STEVEN A YOUNG:CONV001654 [13-005393]

代表美国国立卫生研究院16个研究所和中心的美国国立卫生研究院神经科学研究蓝图，宣布了一项神经治疗学大挑战，以解决神经系统疾病有效药物缺乏的问题。为了迎接这一重大挑战，美国国立卫生研究院蓝图正在开创一种新的药物开发模式——一个将行业药物开发专业知识与创新疾病生物学（这是美国国立卫生研究院资助的研究的优势）相结合的网络。Blueprint神经治疗网络将作为一个“虚拟制药公司”（http://neuroscienceblueprint.nih.gov/bpdrugs/index.htm）运作。具有令人信服的治疗原理和药物开发项目起始材料的神经科学研究人员（主要研究人员）将与设计和指导药物开发计划的资深行业经验丰富的顾问相匹配。主要研究人员将进行生物活性分析和生物学工作，由美国国立卫生研究院通过单独的合同确定和资助的合同研究组织（cro）将执行所有其他药物开发活动。参与项目的首席研究员、顾问、NIH工作人员和CRO工作人员将组成领导开发团队（Lead Development Team， LDT）。

the NIH Blueprint for Neuroscience Research, representing sixteen NIH Institutes and Centers, announced a Grand Challenge for Neurotherapeutics to address the paucity of effective drugs for disorders of the nervous system. To meet this Grand Challenge, the NIH Blueprint is pioneering a new model for drug development�a network that integrates industry drug development expertise with the innovative disease biology that is the strength of NIH-funded research. The Blueprint Neurotherapeutics Network will operate as a �virtual pharma� (http://neuroscienceblueprint.nih.gov/bpdrugs/index.htm). Neuroscience researchers (principal investigators) with a compelling therapeutic rationale and starting materials for a drug development project will be matched with senior-level, industry-seasoned consultants who will design and direct the drug development plan. The principal investigators will conduct the bioactivity assays and biological work, and Contracted Research Organizations (CROs), which will be identified and funded by NIH through separate contracts, will implement all other drug development activities. The principal investigator, consultants, NIH staff, and CRO staff engaged in a project will constitute a Lead Development Team (LDT).